Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 557-566, December 2009

Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?

  • Stephen J. Forman, MD (Chair and Director, Clinical Research)

      Affiliations

    • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States
    • Department of Cancer Immunotherapeutics & Tumor Immunology, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Road, Duarte, CA 91010, United States
    • Corresponding Author InformationTel.: +001 626 256 4673x62405; Fax: +001 626 3018256.

Although allogeneic transplantation is a potentially curative therapy for adults with acute lymphoblastic leukemia (ALL), the high risk of the ablative regimen limits its use, especially in older patients where the need for better therapy is greatest. Recent observations suggesting that a donor derived graft vs leukemia effect is important is facilitating cure after an allogeneic transplant has kindled interest in utilizing a reduced-intensity approach, which relies in large part on this effect to control and cure the disease. Several trials have now been reported that suggest that a reduced-intensity conditioning (RIC) approach might be very effective, especially in patients who are in the first remission of the disease from either related, unrelated, or cord blood transplant donors, with approximately 50% of patients alive and in remission two years after transplant. These studies suggest that prospective studies of RIC should be conducted in patients with ALL in first remission who are at high risk for relapse based on age or comorbidity to determine its role in the overall management of adult patients with this disease.

Keywords: acute lymphoblastic leukemia, graft vs leukemia, pre-B ALL, total body irradiation, reduced intensity transplant

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(09)00076-0

doi:10.1016/j.beha.2009.10.006

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 557-566, December 2009